Table 1 Clinicopathologic characteristics of the patients
Factors | No. | % |
|---|---|---|
Patients enrolled | 515 | 100.0 |
Age (mean ± SD) | 55.5 ± 11.5 |  |
Tumor size | Â | Â |
   Tis | 6 | 1.2 |
   T0 | 3 | 0.6 |
   T1 | 193 | 37.5 |
   T2 | 272 | 52.8 |
   T3 | 34 | 6.6 |
   T4 | 7 | 1.3 |
Lymphnode metastasis | Â | Â |
   negative | 342 | 66.4 |
   positive | 173 | 33.6 |
Lymphatic involvement | Â | Â |
   negative | 316 | 61.4 |
   positive | 199 | 38.6 |
Vascular involvement | Â | Â |
   negative | 481 | 93.4 |
   positive | 34 | 6.6 |
Nuclear grade | Â | Â |
   I/II | 346 | 67.2 |
   III | 169 | 32.8 |
Hormone receptor | Â | Â |
   negative | 123 | 23.9 |
   positive | 392 | 76.1 |
HER-2/NEU | Â | Â |
   negative | 319 | 61.9 |
   positive | 50 | 9.7 |
   unknown | 146 | 28.4 |
CEA | Â | Â |
   <5.0 | 452 | 87.8 |
   >5.1 | 24 | 4.7 |
   unknown | 39 | 7.5 |
Stage | Â | Â |
   0 | 6 | 1.2 |
   I | 155 | 30.1 |
   II | 316 | 61.3 |
   III | 38 | 7.4 |
Recurrence | Â | Â |
   negative | 438 | 85.0 |
   positive | 77 | 15.0 |
Prognosis | Â | Â |
   alive | 488 | 94.8 |
   dead | 27 | 5.2 |